These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15864230)

  • 21. Drug-eluting stent-supported percutaneous coronary intervention for chronic total coronary occlusion.
    Migliorini A; Moschi G; Vergara R; Parodi G; Carrabba N; Antoniucci D
    Catheter Cardiovasc Interv; 2006 Mar; 67(3):344-8. PubMed ID: 16489559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TCT Daily: ZOMAXX I--mixed results with zotarolimus-eluting stent.
    J Interv Cardiol; 2007 Feb; 20(1):35. PubMed ID: 17300399
    [No Abstract]   [Full Text] [Related]  

  • 23. Stent thrombosis in the era of drug eluting stents.
    Kawaguchi R; Angiolillo DJ; Futamatsu H; Suzuki N; Bass TA; Costa MA
    Minerva Cardioangiol; 2007 Apr; 55(2):199-211. PubMed ID: 17342038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent restenosis in the era of drug-eluting stents.
    Ajani AE; Yan BP; Clark DJ; Eccleston D; Walton A; Lew R; Meehan A; Brennan A; Reid C; Duffy SJ;
    Heart Lung Circ; 2007 Aug; 16(4):269-73. PubMed ID: 17419097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on drug-eluting coronary stents.
    Kipshidze NN; Tsapenko MV; Leon MB; Stone GW; Moses JW
    Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):953-68. PubMed ID: 16181039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent.
    Kandzari DE; Leon MB
    J Interv Cardiol; 2006 Oct; 19(5):405-13. PubMed ID: 17020565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of the TAXUS Liberté SR paclitaxel-eluting coronary stent.
    Ahmed WH
    Expert Rev Med Devices; 2007 Mar; 4(2):117-20. PubMed ID: 17359218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental efficacy of an everolimus eluting cobalt chromium stent.
    Carter AJ; Brodeur A; Collingwood R; Ross S; Gibson L; Wang CA; Haller S; Coleman L; Virmani R
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):97-103. PubMed ID: 16755598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Late stent thromboses a neglected problem? Indications of increased risk with drug-eluting stents].
    Stenestrand U
    Lakartidningen; 2006 Sep 27-Oct 3; 103(39):2838-9. PubMed ID: 17128915
    [No Abstract]   [Full Text] [Related]  

  • 30. Release profiles in drug-eluting stents: issues and uncertainties.
    Venkatraman S; Boey F
    J Control Release; 2007 Jul; 120(3):149-60. PubMed ID: 17582635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Full metal jacket" (stented length > or =64 mm) using drug-eluting stents for de novo coronary artery lesions.
    Aoki J; Ong AT; Rodriguez Granillo GA; McFadden EP; van Mieghem CA; Valgimigli M; Tsuchida K; Sianos G; Regar E; de Jaegere PP; van der Giessen WJ; de Feyter PJ; van Domburg RT; Serruys PW
    Am Heart J; 2005 Nov; 150(5):994-9. PubMed ID: 16290984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of stent design and coatings on restenosis and thrombosis.
    Hara H; Nakamura M; Palmaz JC; Schwartz RS
    Adv Drug Deliv Rev; 2006 Jun; 58(3):377-86. PubMed ID: 16650911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison.
    Mauri L; Orav EJ; Kuntz RE
    Circulation; 2005 Jun; 111(25):3435-42. PubMed ID: 15967844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postmarket surveillance for drug-eluting coronary stents: a comprehensive approach.
    Baim DS; Mehran R; Kereiakes DJ; Gross TP; Simons M; Malenka D; Kaplan AV
    Circulation; 2006 Feb; 113(6):891-7. PubMed ID: 16476863
    [No Abstract]   [Full Text] [Related]  

  • 35. Factors predictive of cardiac events and restenosis after sirolimus-eluting stent implantation in small coronary arteries.
    Lee CW; Suh J; Lee SW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2007 May; 69(6):821-5. PubMed ID: 17191211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of patients with in-stent restenosis.
    Alfonso F; Pérez-Vizcayno MJ; Cruz A; García J; Jimenez-Quevedo P; Escaned J; Hernandez R
    EuroIntervention; 2009 May; 5 Suppl D():D70-8. PubMed ID: 19736076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
    Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A
    Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The average stent length is longer and the average stent diameter is shorter in patients with drug-eluting stents versus bare-metal stents during percutaneous coronary intervention.
    Dilmanian H; Aronow WS; Mundia M; Pucillo AL; Weiss MB; Kalapatapu K; Monsen CE
    Am J Ther; 2007; 14(3):277-9. PubMed ID: 17515704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: randomized controlled prospective study.
    Han SH; Ahn TH; Kang WC; Oh KJ; Chung WJ; Shin MS; Koh KK; Choi IS; Shin EK
    Am Heart J; 2006 Nov; 152(5):887.e1-7. PubMed ID: 17070150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.